Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. Systematic review of real-life mortality in t...
Main Authors: | Senta Frol, Dimitrios Sagris, Mišo Šabovič, George Ntaios, Janja Pretnar Oblak |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.727403/full |
Similar Items
-
Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
by: Esme Ekizoğlu
Published: (2018-06-01) -
Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study
by: Nils Kuklik, et al.
Published: (2023-07-01) -
Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
by: Valentin Held, et al.
Published: (2016-10-01) -
Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
by: Jhih-Wei Dai, et al.
Published: (2023-05-01) -
The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)